Symbols

CPRX

Catalyst·NASDAQ

--(--)

CPRX fundamentals

CPRX Q4 2025 Earnings

Catalyst (CPRX) released its earnings on Feb 25, 2026: revenue was 152.50M (YoY +7.54%), beat estimates; EPS was 0.41 (YoY -6.82%), beat estimates.

Revenue / YoY

152.50M

+7.54%

EPS / YoY

0.41

-6.82%

Report date

Feb 25, 2026

CPRX Earnings Call Summary for Q4,2025

Revenue Growth: 19.8% YoY to $589M, driven by FIRDAPSE (+17%) and AGAMREE (+154%).
2026 Outlook: FIRDAPSE up 21-26%, AGAMREE up 19-28%, FYCOMPA down to $40-45M.
Strategic Initiatives: 600+ LEMS patients in pipeline, 21% VGCC test growth, and 12% reduction in FIRDAPSE discontinuations.
Financial Strength: $709M cash, Non-GAAP EPS $2.72, and 37% YoY cash growth.
Pipeline Potential: SUMMIT trial enrollment for AGAMREE, Phase 1a immunosuppression study, and 100+ BD opportunities.

Earnings

EPS

Revenue

Revenue & Expenses

CPRX has released its 2025 Q4 earnings report, with revenue of 152.61M, reflecting a YoY change of 7.61%, and net profit of 52.70M, showing a YoY change of -5.79%. The Sankey diagram below clearly presents CPRX's revenue sources and cost distribution.

Key Indicators

Catalyst (CPRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Catalyst (CPRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Catalyst (CPRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Catalyst (CPRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown